PANGYO, South Korea, Feb. 23, 2024 /PRNewswire/ — Oscotec Inc. and ADEL Inc. announced the dosing of the first healthy participant in its first-in-human study of ADEL-Y01 for the treatment of Alzheimer’s disease (AD). Oscotec and ADEL are jointly developing a novel disease-modifying immunotherapy agent (ADEL-Y01) targeting tau protein accumulation...
Latest News
Nantes – OSE Immunotherapeutics (FR0012127173) and the French cooperative group ARCAGY-GINECO today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethic Committee (CPP) approved the initiation of a new Phase 2 clinical trial evaluating Tedopi® in patients with recurrent ovarian cancer...
Compared with afatinib, treatment with osimertinib demonstrates better survival outcomes for patients with T790M-positive non-small cell lung cancer (NSCLC) that does not initially respond to initial epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), according to study results published in BMC Pulmonary Medicine. A team of investigators in China conducted a...
Norman, Oklahoma – Researchers at OU Health Stephenson Cancer Center at the University of Oklahoma Health Sciences have embarked on a revolutionary new research study that could improve the detection of a deadly disease — pancreatic cancer — and give patients a chance to live longer, healthier lives. The research...
Evanston, Illinois — Women diagnosed with ovarian cancer may initially respond well to chemotherapy, but the majority of them will develop resistance to treatment and die from the disease. Now Northwestern Medicine scientists have discovered the Achilles heel of chemotherapy-resistant ovarian cancer — its hunger for cholesterol — and how...
Oxford, UK and San Jose, Calif. – Oxford BioTherapeutics (‘OBT’), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based therapies, today announces that the first patient has been dosed in a Phase 1b trial investigating OBT’s lead candidate, OBT076, in patients with Adenoid Cystic Carcinoma...
DALLAS – A simple magnetic resonance imaging (MRI) test involving breathing oxygen might help oncologists determine the best treatment for some cancer patients, report researchers at UT Southwestern Medical Center. Prior research has shown that the amount of oxygen present in a tumor can be a predictor of how well...
Menlo Paqqrk, Calif. — PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, announced a new informatics method that genotypes gene paralogs and pseudogenes with high accuracy. The new computational tool, named “Paraphase,” enables variant calling, copy number analysis and phasing by identifying the full gene sequence of each...
TAMPA, Fla. — Pacira Biosciences Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to PCRX-201 (enekinragene inzadenovec), the company’s novel, intra-articular helper-dependent adenovirus...
Edmonton, Canada – Pacylex Pharmaceuticals Inc. (Pacylex) is a clinical-stage pharmaceutical company focused on the development of a new class of targeted therapies, N-myristoyltransferase inhibitors (NMTi) for the treatment of hematologic and solid tumor cancers. Today Pacylex announced that the results of its Phase 1 dose escalation safety and tolerability...